Shavadia JS, Zheng Y, Green JB, et al. - Researchers examined links between beta-blocker therapy in type 2 diabetes (T2D) with atherosclerotic cardiovascular disease (ASCVD) and cardiovascular (CV) outcomes among participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin. For this purpose, they used an inverse probability of treatment-weighted Cox proportional hazards model. They randomized 14,671 patients who were observed over a median duration of 3 years. Of these patients, 64% were receiving a beta-blocker at baseline. Furthermore, the probability of having prior myocardial infarction or heart failure was greater in these patients. The researchers did not identify any link of baseline beta-blocker use with risks for severe hypoglycemia in this observational study of T2D and ASCVD, and no link was evident between baseline beta-blocker use and decrease in CV risk over 3 years of follow-up.